2026 ASH®
Annual Meeting & Exposition December 12-15, 2026 ▪ New Orleans, Louisiana

Paper Details

Abstracts, authors, affiliations, and disclosures.

SESSION

655. Multiple Myeloma: Cellular Therapies: Poster I

Program: Poster Abstract Session
Saturday, December 12, 2026
05:30 p.m. - 07:30 p.m.
MCCNO - Hall F
Access, Representation, Population Health, Technology and Procedures, Clinical Procedures, Emerging Technologies, Treatment Considerations, Biological Therapies, Bispecific Antibody Therapy, Chimeric Antigen Receptor, (CAR)-T Cell Therapies, Immunotherapy, Adverse Events, Clinical Practice (Health Services and Quality), Patient Safety, Quality Improvement, Diseases, Infectious Diseases, Lymphoid Malignancies, Lymphomas, Plasma Cell Disorders, B Cell Lymphoma, Research, Clinical Research, Clinical Trials, Epidemiology, Health Outcomes Research, Real-World Evidence, Registries, Study Population, Human, Adult
PAPER

2269 Long-term outcomes after BCMA CAR T-cell therapy for relapsed/refractory multiple myeloma

Li Lin, MD, Mingming Zhang, PhD2, Shan Fu3, Alex H. Zhang, Dr.4, He Huang, MD, PhD5, Yongxian HU, MD6
1 Bone Marrow Transplantation Center, The First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, Zhejiang, China, The Affiliated People's Hospital of Ningbo University, Ningbo, Zhejiang, China
2 Bone Marrow Transplantation Center, The First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, Zhejiang, China
3 Bone Marrow Transplantation Center, The First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, Zhejiang, China
4 Shanghai YaKe Biotechnology Ltd, Shanghai, China
5 Bone Marrow Transplantation Center, The First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, Zhejiang, China
6 Bone Marrow Transplantation Center, The First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, Zhejiang, China

Background
    B-cell maturation antigen (BCMA)-targeted chimeric antigen receptor (CAR) T-cell therapy has shown remarkable efficacy in patients with relapsed/refractory multiple myeloma (RRMM). However, the durability of long-term response following BCMA CAR T-cell therapy remains incompletely characterized. Here,we report the clinical characteristics and outcomes of patients who achieved long-term remission following BCMA CAR T-cell therapy for RRMM.
Method
   This study included long-term follow-up data from the clinical trial cohort (ChiCTR1800017404). Between July 30, 2018, and July 31, 2022, a total of 100 patients with RRMM received BCMA CAR T-cell therapy at our center. No patients received subsequent anti-myeloma therapy after CAR T-cell infusion. CAR T cells were generated from autologous T cells and engineered using a lentiviral vector to express a second-generation BCMA CAR containing a 4-1BB costimulatory domain and a CD3ζ signaling domain. Long-term response was defined as progression-free survival (PFS) ≥48 months after CAR T-cell infusion. PFS was defined as the time from CAR T-cell infusion to disease progression or death from any cause, and overall survival (OS) was defined as the time from infusion to death from any cause. Late disease progression was defined as disease progression occurring after achieving PFS of ≥48 months. PFS and OS were estimated using the Kaplan–Meier method. Median follow-up was calculated using the reverse Kaplan–Meier method, and 95% confidence intervals were estimated using the Greenwood formula with log-log transformation.
Result
    As of July 31, 2026, the median follow-up duration for the entire cohort was 78.5 months (range,69.8-87.1). The median PFS and OS were 12.0 months (range, 7.4–16.6) and 47.0 months (range, 40.4–53.7), respectively. The estimated 5-year PFS and OS rates were approximately 16% and 37.8%, respectively. Kaplan–Meier analysis demonstrated that the occurrence of PFS and OS events decreased substantially after approximately 60 months and subsequently plateaued, indicating the presence of a subset of patients achieving durable response after CAR T-cell therapy.
    At data cutoff, 21 of 100 patients (21.0%) were classified as long-term response. Among these 21 patients, 15 (71.4%) maintained sustained remission, 2 (9.5%) were alive after late disease progression, and 4 (19.0%) died. The causes of death included MM progression (n=2), COVID-19 infection (n=1), and hepatocellular carcinoma (n=1). No significant differences were observed between long-term remission patients and other patients in baseline characteristics, including age, Durie–Salmon stage, bone marrow plasma cell proportion, high-risk cytogenetic abnormalities, number of prior treatment lines, and history of autologous stem cell transplantation (ASCT) (all P > 0.05). The proportion of patients with extramedullary disease was significantly lower in the long-term remission patients than in other patients (23.8% vs. 58.2%, P = 0.005).Among the 21 patients with long-term remission, median PFS and OS were not reached. The estimated 72-month PFS and OS rates were 70.3% and 79.1%, respectively. 15 patients had remained disease-free for more than 5 years, with a median progression-free observation time of 83.0 months (range, 60.5–93.1). Peak CAR T-cell expansion levels and peak CAR T-cell expansion day did not differ significantly between the long-term remission patients and other patients.The incidences of CRS, grade ≥2 CRS, and ICANS did not differ significantly between two groups.
Conclusion
    Long-term follow-up data from our center demonstrate that BCMA CAR T-cell therapy can induce durable responses in a subset of patients with RRMM. These findings are encouraging and provide supportive evidence toward the goal of achiving cure in RRMM.

Li Lin, MD: No relevant conflicts of interest to declare.